相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Lisa M. Rice et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders
Michele Iudici et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Suzana Jordan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review
Mohammed A. Omair et al.
PLOS ONE (2015)
Treatment of systemic sclerosis with tocilizumab
Marisa Fernandes das Neves et al.
RHEUMATOLOGY (2015)
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
Zarir F. Udwadia et al.
LUNG INDIA (2015)
Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease A Systematic Review
Tiffany A. Winstone et al.
CHEST (2014)
Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series
Neslihan Yilmaz et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2014)
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis A Randomized Clinical Trial
Jacob M. van Laar et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels
Serena Vettori et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Mortality and survival in systemic sclerosis: Systematic review and meta-analysis
Manuel Rubio-Rivas et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Paolo Fraticelli et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand
Mohan S. Maddur et al.
NATURE COMMUNICATIONS (2014)
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Interleukin-13-producing CD8+T cells mediate dermal fibrosis in patients with systemic sclerosis
Patrizia Fuschiotti et al.
ARTHRITIS AND RHEUMATISM (2013)
Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
Angelo De Lauretis et al.
JOURNAL OF RHEUMATOLOGY (2013)
Autologous HSCT for systemic sclerosis
Jacob M. van Laar et al.
LANCET (2013)
Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study
Stylianos T. Panopoulos et al.
LUNG (2013)
Survival after lung transplantation in systemic sclerosis. A systematic review
Irfan Y. Khan et al.
RESPIRATORY MEDICINE (2013)
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
Owen A. Moore et al.
RHEUMATOLOGY (2013)
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
Korsa Khan et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Racial differences between blacks and whites with systemic sclerosis
Richard M. Silver et al.
CURRENT OPINION IN RHEUMATOLOGY (2012)
Chitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF-β1 Signaling
Chun Geun Lee et al.
JOURNAL OF IMMUNOLOGY (2012)
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab
Wan-Hee Yoo
RHEUMATOLOGY INTERNATIONAL (2012)
Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis
Hadi Poormoghim et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis
Argyris Tzouvelekis et al.
PULMONARY MEDICINE (2012)
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
Robert F. Spiera et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Cigarette Smoking in Patients With Systemic Sclerosis
Marie Hudson et al.
ARTHRITIS AND RHEUMATISM (2011)
A One-Year, Phase I/IIa, Open-Label Pilot Trial of Imatinib Mesylate in the Treatment of Systemic Sclerosis-Associated Active Interstitial Lung Disease
Dinesh Khanna et al.
ARTHRITIS AND RHEUMATISM (2011)
Integrating mechanisms of pulmonary fibrosis
Thomas A. Wynn
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial
Richard K. Burt et al.
LANCET (2011)
A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al Reply
James R. Seibold et al.
ARTHRITIS AND RHEUMATISM (2010)
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
Yoshihito Shima et al.
RHEUMATOLOGY (2010)
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
Silvia Bosello et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFβ Expression
Timothy R. D. J. Radstake et al.
PLOS ONE (2009)
The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications
Sophie P. Toya et al.
RHEUMATOLOGY INTERNATIONAL (2009)
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials
Karen Au et al.
Current Rheumatology Reports (2009)
CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma
Ayumi Yoshizaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Interstitial lung disease in systemic sclerosis - A simple staging system
Nicole S. L. Goh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice
Fumitake Saito et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
Carlotta Nannini et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts
Xu Shi-wen et al.
ARTHRITIS AND RHEUMATISM (2007)
Changes in causes of death in systemic sclerosis, 1972-2002
Virginia D. Steen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type a receptor-mediated production of TGF-β1
Raksha Jain et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease
Brigham C. Willis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2007)
Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
Christopher P. Denton et al.
ARTHRITIS AND RHEUMATISM (2007)
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
U. A. Walker et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Rachel K. Hoyles et al.
ARTHRITIS AND RHEUMATISM (2006)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis
O Nadashkevich et al.
CLINICAL RHEUMATOLOGY (2006)
The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
T Yamamoto
ARCHIVES OF DERMATOLOGICAL RESEARCH (2006)
Scleroderma: from cell and molecular mechanisms to disease models
DJ Abraham et al.
TRENDS IN IMMUNOLOGY (2005)
T cell repertoire in patients with stable scleroderma
KP Tiev et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: Role of IL-4/IL-13 and mediation via STAT-6
TJ Liu et al.
JOURNAL OF IMMUNOLOGY (2004)
Fibrotic disease and the TH1/TH2 paradigm
TA Wynn
NATURE REVIEWS IMMUNOLOGY (2004)
Altered blood B lymphocyte Homeostasis in systemic sclerosis - Expanded naive B cells and diminished but activated memory B cells
S Sato et al.
ARTHRITIS AND RHEUMATISM (2004)
Is systemic sclerosis an antigen-driven T cell disease?
LI Sakkas et al.
ARTHRITIS AND RHEUMATISM (2004)
Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells
C Jakubzick et al.
JOURNAL OF IMMUNOLOGY (2003)
Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+T cells from scleroderma patients
IG Luzina et al.
ARTHRITIS AND RHEUMATISM (2003)
Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities
V Riccieri et al.
CLINICAL RHEUMATOLOGY (2003)
Predictors of end stage lung disease in a cohort of patients with scleroderma
C Morgan et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis
S Nagai et al.
INTERNAL MEDICINE (2002)
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome
D Bouros et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension
M Bauer et al.
CIRCULATION (2002)
Nonspecific interstitial pneumonia and usual interstitial pneumonia: Comparative appearances at and diagnostic accuracy of thin-section CT
SLS MacDonald et al.
RADIOLOGY (2001)
Quantitative genetic variation in CD19 expression correlates with autoimmunity
S Sato et al.
JOURNAL OF IMMUNOLOGY (2000)
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice
B Hocher et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2000)
分享论文
